Guardant is another Cathie Wood stock that stands to grow into the huge market for preventative cancer screening. The company uses proprietary blood-based tests and advanced analytics to manage ...

Cathie Wood is having another rough year. ... Shield is a simple blood test. Guardant products completed 202,800 clinical or biopharmaceutical tests last year, ...

At that time, Cathie Wood's portfolio may reap the rewards in a big way -- and if you follow her into this innovative company now, your portfolio may, too. Should you invest $1,000 in Moderna ...

At least that's what Cathie Wood's recent purchases suggest. ... Medicare and other end payers are generally keen to pay $2,841 for the blood-based test because it's still cheaper than the ...